NiCCC
Trial Description:
A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium
Lead Cooperative Group:
Trial Number:
Disease Site:
Recurrent Ovarian / Rare
Trial Status:
Closed to Recruitment
Contact person:
rglasspool